

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants: Schrimpf, et al.

Serial No.: 09/833,914

Filed: April 12, 2001

Title: DIAZABICYCLIC CENTRAL  
NERVOUS SYSTEM ACTIVE AGENTS

Case No.: 6696US02



Group Art No.: 1624

Examiner: Coleman, Brenda Libby

I hereby certify that this paper (along with any paper referred to as  
being attached or enclosed) is being deposited with the United States  
Postal Service on the date shown below with sufficient postage as  
first class mail in an envelope addressed to the:

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: March 26, 2004

Tanya Parent 3/26/04  
Tanya Parent Date

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:


Enclosed herewith for the patent application identified above entitled DIAZABICYCLIC  
CENTRAL NERVOUS SYSTEM ACTIVE AGENTS are the following:

1. Request for Continued Examination (RCE) Transmittal;
2. Information Disclosure Statement;
3. Form PTO 1449, in duplicate;
4. References as cited on PTO 1449 (11 references); and
5. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required  
under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17  
associated with this communication for which full payment had not been tendered, to Deposit  
Account No. 01-0025.

Respectfully submitted,  
Schrimpf, et al.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-8272  
Facsimile: (847) 938-2623

  
Portia Chen  
Registration No. 44,075  
Attorney for Applicants

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants: Schrimpf, et al.

Serial No.: 09/833,914

Filed: April 12, 2001

Title: DIAZABICYCLIC CENTRAL  
NERVOUS SYSTEM ACTIVE AGENTS

Case No.: 6696US02



Group Art No.: 1624

Examiner: Coleman, Brenda Libby

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: March 26, 2004

Tanya Parent 3/26/04  
Tanya Parent Date

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,  
Schrimpf, et al.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-8272  
Facsimile: (847) 938-2623

  
Portia Chen  
Registration No. 44,075  
Attorney for Applicants



DATE: March 26, 2004 SHEET \_1\_ of \_1\_

## Form PTO - 1449 (Modified)

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE</b>	<b>ATTY. DOCKET NO.</b>	<b>SERIAL NO.</b>
	<b>6696US02</b>	<b>09/833,914</b>
	<b>APPLICANT(S)</b>	
	<b>Schrimpf, et al.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>FILING DATE</b>	<b>GROUP</b>
	<b>April 12, 2001</b>	<b>1624</b>

(Use several sheets if necessary)

(37 CFR 1.98 (b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1 00/34284	15.06.2000	WO			
	B2 00/44755	03.08.2000	WO			
	B3 00/66586	09.11.2000	WO			
	B4 00/71534	30.11.2000	WO			
	B5 01/44243	21.06.2001	WO			
	B6 96/06093	29.02.1996	WO			
	B7 97/05139	13.02.1997	WO			
	B8 99/21834	06.05.1999	WO			
	B9 99/32117	01.07.1999	WO			
	B10 99/51602	14.10.1999	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Decker et al., "Therapeutic potential of Neuronal Nicotinic Acetylcholine Receptor Agonists As Novel Analgesics," Biochemical Pharmacology 58:917-923 (1999)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)